Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

NICEweb

Thalidomide recommended ahead of Velcade

June 2, 2010
Medical Communications NICE, myeloma

Celgene’s Thalidomide has been recommended by NICE as a treatment for multiple myeloma, and is favoured ahead of Janssen-Cilag’s Velcade. …

News

NICE rejects Bayer’s liver cancer drug

May 26, 2010
Sales and Marketing NICE, Nexavar, patient access scheme

Bayer’s liver cancer drug Nexavar has been rejected by NICE after it deemed the drug too costly for a marginal …

News

NICE responds to Daily Mail cancer drug claims

April 12, 2010
Sales and Marketing NICE, Sutent, election, off label

NICE has responded to a Daily Mail article on access to cancer drugs, in order to clear up claims of …

News
Cameron talks to cancer patient

Conservative claims on cancer drugs disputed

April 6, 2010
Sales and Marketing NHS, NICE, election

A think tank has disputed Conservative claims that funds can be diverted to pay for greater access to new cancer …

News

NICE changes its mind on Multaq

March 30, 2010
Sales and Marketing Multaq, NICE, Sanofi-Aventis

NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …

News
Glivec pack

NICE seeks compromise over Glivec approval

March 24, 2010
Sales and Marketing Glivec, NICE, Novartis

NICE says it is unlikely to approve the use of Glivec against gastrointestinal stromal tumours (GISTs) after surgery, but is …

News

Conventional hypertension prescribing ‘should be reconsidered’

March 16, 2010
NICE, hypertension

New findings throwing doubt on conventional wisdom about high blood pressure may have implications for NICE’s advice on hypertension. Published …

News

Vidaza too costly for NICE

March 8, 2010
Sales and Marketing Celgene, NICE, Vidaza

NICE has rejected Celgene’s Vidaza for use on the NHS to treat the rare bone marrow disease myelodysplastic syndrome. The …

News

NICE approves Yondelis

February 24, 2010
Sales and Marketing NICE, PharmaMar, Yondelis

Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to …

News
Victoza pack

Novo to challenge NICE Victoza guidance

February 15, 2010
Sales and Marketing NICE, Novo Nordisk, Victoza

NICE has given a partial green light to Novo Nordisk’s type II diabetes treatment Victoza, backing its use as part …

News

NICE warns industry on cost-effectiveness

February 9, 2010
Sales and Marketing BMS, Janssen, NICE, Novartis, hta

NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help …

News

Servier fails to overturn NICE osteoporotic guidance

February 2, 2010
Sales and Marketing NICE, Servier, osteoporosis

Servier’s challenge to NICE guidance on preventing osteoporotic fractures has proved unsuccessful, with the watchdog’s original decision still standing. This …

News

Patient access scheme secures NICE approval for Cimzia

January 22, 2010
Sales and Marketing Cimzia, NICE, UCB, rheumatoid arthritis

UCB Pharma’s Cimzia has been recommended by NICE to treat rheumatoid arthritis – but only if a patient access scheme …

News

NICE approves Trabectedin

January 19, 2010
Sales and Marketing NICE, PharmaMar, Trabectedin, soft tissue sarcoma

Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval. …

News

NICE to revamp chronic heart failure guidance

January 18, 2010
NHS, NICE, chronic heart failure

NICE is moving to update its clinical guidance on the management of chronic heart failure in adults. Draft recommendations are …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026